AcelRx Pharmaceuticals Inc  

(Public, NASDAQ:ACRX)   Watch this stock  
Find more results for ACRX
2.08
+0.03 (1.22%)
Nov 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.05 - 2.15
52 week 1.55 - 5.75
Open 2.10
Vol / Avg. 687,350.00/2.69M
Mkt cap 104.45M
P/E     -
Div/yield     -
EPS -1.12
Shares 50.34M
Beta 2.87
Inst. own 34%
Nov 9, 2017
Q3 2017 AcelRx Pharmaceuticals Inc Earnings Call - Webcast
Oct 12, 2017
AcelRx Pharmaceuticals, Inc. - Special Call - Webcast
Sep 27, 2017
AcelRx Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 26, 2017
AcelRx Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference
Sep 11, 2017
AcelRx Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -875.12% -248.64%
Operating margin -595.90% -184.12%
EBITD margin - -172.29%
Return on average assets -64.87% -37.89%
Return on average equity - -310.75%
Employees 39 -
CDP Score - -

Address

351 Galveston Dr
REDWOOD CITY, CA 94063-4736
United States - Map
+1-650-2163500 (Phone)
+1-650-2166500 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Officers and directors

Adrian Adams Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Richard A. King President
Age: 52
Bio & Compensation  - Reuters
Vincent J. Angotti Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Raffi M. Asadorian Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Pamela P. Palmer M.D. Ph.D. Chief Medical Officer, Director
Age: 52
Bio & Compensation  - Reuters
Badri N. Dasu Chief Engineering Officer
Age: 52
Bio & Compensation  - Reuters
Lawrence G. Hamel Chief Development Officer
Age: 63
Bio & Compensation  - Reuters
Jane Wright-Mitchell Chief Legal Officer
Age: 46
Bio & Compensation  - Reuters
Richard F. Afable M.D. Director
Age: 61
Bio & Compensation  - Reuters
Howard B. Rosen Director
Age: 59
Bio & Compensation  - Reuters